GUARDION HLTH SCIENCS INC - GHSI STOCK NEWS

Guardion Health Sciences has appointed Craig J. Sheehan as Chief Commercial Officer. Sheehan, previously responsible for the successful Viactiv brand at Adare Pharmaceuticals, will oversee commercialization strategies following Guardion's acquisition of Activ Nutritional. With a strong background in marketing and brand growth, his leadership aims to enhance Guardion's market presence in the clinical nutrition sector. CEO Bret Scholtes expressed confidence in Sheehan's capabilities to strengthen the company's marketing initiatives, vital for long-term success.

Guardion Health Sciences, Inc. (GHSI) has completed its acquisition of Activ Nutritional, LLC from Adare Pharmaceuticals for $26 million. This strategic move aims to enhance Guardion's position in the clinical nutrition market, specifically through the Viactiv® line of mineral supplements. The acquisition is expected to significantly boost Guardion's operational revenues and expand its marketing capabilities across various distribution channels. Guardion plans to explore further growth opportunities within clinical nutrition, moving beyond its ocular health focus.

Guardion Health Sciences (NASDAQ: GHSI) announced that CEO Bret Scholtes will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. Scholtes’ presentation is scheduled for June 9 at 12:30 PM ET, Track 2. Investors can register to attend the presentation through the provided link. Guardion specializes in clinical nutrition, supplements, and diagnostics aimed at supporting health goals, with a strong advisory board of experienced professionals in the healthcare sector.

Guardion Health Sciences (GHSI) announced an acquisition of Activ Nutritional, LLC for $26 million as part of its growth strategy in the clinical nutrition market. This deal, expected to close by June 30, 2021, will enhance Guardion's product portfolio with the Viactiv supplement line, currently sold at major retailers like Walmart and Amazon. CEO Bret Scholtes emphasized that this acquisition expands Guardion's market presence beyond ocular health, boosting revenue and operating earnings while allowing exploration of additional opportunities in clinical nutrition.

Guardion Health Sciences (GHSI) reported financial results for Q1 2021, with total revenue of $233,297, down 5% from the previous year. The net loss widened to $(2,669,525) or $(0.13) per share, compared to $(2,346,913) or $(0.18) per share in Q1 2020. Cash reserves stood at $43,329,674. The company completed a $35 million equity financing and initiated a clinical trial for its GlaucoCetin® product. Recent product approvals in Malaysia for its immune support supplements are expected to bolster growth.

Guardion Health Sciences (Nasdaq: GHSI) has launched a placebo-controlled clinical trial assessing the efficacy of GlaucoCetin® in improving visual function in glaucoma patients. This 12-week study will involve 100 participants, evaluating changes in visual field sensitivity and quality of life among those with central or peripheral vision loss. The trial aims to support Guardion's focus on developing clinically backed medical foods aimed at enhancing mitochondrial activity in optic nerve cells, which are critical for vision.

Guardion Health Sciences (GHSI) reported a significant revenue increase of 109% for 2020, totaling $1,889,844 compared to $902,937 in 2019. Despite this growth, the company faced a net loss of $(8,571,657), although this was an improvement from $(10,878,308) in 2019. The company undertook a 1-for-6 reverse stock split effective March 1, 2021, to comply with Nasdaq listing rules. Recent financing raised $35 million to support growth and strategic acquisitions, with a cash balance of $45.7 million post-financing.

Guardion Health Sciences (GHSI) has successfully regained compliance with Nasdaq's minimum bid price requirement on March 15, 2021, after its common stock closed above $1.00 per share for ten consecutive trading days. This follows a history of non-compliance starting from September 2019, with extensions granted due to COVID-19 impacts. The company had faced potential delisting but responded timely to Nasdaq’s notifications, securing its continued listing.

Guardion Health Sciences, Inc. (NASDAQ: GHSI) announced that CEO Bret Scholtes will present at Maxim Group's Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. Investors can register to view the presentation and request a 1x1 meeting with Scholtes post-conference. Guardion specializes in clinical nutrition and diagnostics, offering evidence-based nutritional supplements and medical foods. The company's growth is backed by a strong advisory board and aims to enhance health outcomes, particularly in the eye care industry.